Apellis Pharmaceuticals Stock Annual Yield

APLS Stock

USD 34.14 1.51 4.63%

Apellis Pharmaceuticals fundamentals help investors to digest information that contributes to Apellis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Apellis Stock. The fundamental analysis module provides a way to measure Apellis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Apellis Pharmaceuticals stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Apellis Pharmaceuticals Company Annual Yield Analysis

Apellis Pharmaceuticals' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.

Yield

Income from Security

Current Share Price

More About Annual Yield | All Equity Analysis

Apellis Annual Yield Driver Correlations

Understanding the fundamental principles of building solid financial models for Apellis Pharmaceuticals is extremely important. It helps to project a fair market value of Apellis Stock properly, considering its historical fundamentals such as Annual Yield. Since Apellis Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Apellis Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Apellis Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Property Plant Equipment	Capital Surpluse	Long Term Debt	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Capital Stock	Current Deferred Revenue	Short Term Investments
Total Assets		0.87	-0.86	-0.77	0.69	0.4	0.99	1.0	0.93	0.84	0.97	0.87	0.82	0.88	0.84	-0.85	0.96	-0.82	0.85	-0.5	-0.67
Total Stockholder Equity	0.87		-0.81	-0.69	0.65	0.38	0.79	0.87	0.89	0.95	0.77	0.82	0.61	0.65	0.71	-0.77	0.78	-0.75	0.73	-0.47	-0.6
Net Debt	-0.86	-0.81		0.8	-0.78	-0.33	-0.84	-0.86	-0.92	-0.83	-0.86	-0.86	-0.54	-0.81	-0.56	0.83	-0.79	0.8	-0.84	0.57	0.8
Retained Earnings	-0.77	-0.69	0.8		-0.98	-0.79	-0.76	-0.78	-0.84	-0.76	-0.86	-0.84	-0.46	-0.89	-0.53	0.77	-0.75	0.7	-0.97	0.91	0.96
Accounts Payable	0.69	0.65	-0.78	-0.98		0.77	0.66	0.69	0.8	0.74	0.78	0.82	0.34	0.82	0.41	-0.75	0.64	-0.68	0.92	-0.9	-0.94
Net Receivables	0.4	0.38	-0.33	-0.79	0.77		0.39	0.41	0.48	0.52	0.53	0.61	0.25	0.66	0.31	-0.5	0.41	-0.43	0.67	-0.92	-0.7
Total Liab	0.99	0.79	-0.84	-0.76	0.66	0.39		0.99	0.9	0.77	0.98	0.85	0.84	0.9	0.84	-0.83	0.97	-0.8	0.84	-0.49	-0.66
Total Current Assets	1.0	0.87	-0.86	-0.78	0.69	0.41	0.99		0.93	0.84	0.97	0.88	0.82	0.88	0.84	-0.85	0.96	-0.82	0.85	-0.51	-0.67
Common Stock	0.93	0.89	-0.92	-0.84	0.8	0.48	0.9	0.93		0.89	0.93	0.92	0.59	0.85	0.62	-0.88	0.82	-0.85	0.89	-0.59	-0.76
Net Tangible Assets	0.84	0.95	-0.83	-0.76	0.74	0.52	0.77	0.84	0.89		0.77	0.9	0.62	0.74	0.7	-0.83	0.78	-0.81	0.75	-0.62	-0.67
Property Plant Equipment	0.97	0.77	-0.86	-0.86	0.78	0.53	0.98	0.97	0.93	0.77		0.89	0.76	0.95	0.75	-0.85	0.93	-0.8	0.92	-0.63	-0.77
Capital Surpluse	0.87	0.82	-0.86	-0.84	0.82	0.61	0.85	0.88	0.92	0.9	0.89		0.69	0.92	0.65	-0.95	0.81	-0.93	0.81	-0.67	-0.72
Long Term Debt	0.82	0.61	-0.54	-0.46	0.34	0.25	0.84	0.82	0.59	0.62	0.76	0.69		0.74	0.94	-0.68	0.89	-0.67	0.5	-0.26	-0.29
Long Term Debt Total	0.88	0.65	-0.81	-0.89	0.82	0.66	0.9	0.88	0.85	0.74	0.95	0.92	0.74		0.69	-0.87	0.87	-0.82	0.87	-0.73	-0.78
Net Invested Capital	0.84	0.71	-0.56	-0.53	0.41	0.31	0.84	0.84	0.62	0.7	0.75	0.65	0.94	0.69		-0.63	0.93	-0.61	0.59	-0.35	-0.4
Short Long Term Debt	-0.85	-0.77	0.83	0.77	-0.75	-0.5	-0.83	-0.85	-0.88	-0.83	-0.85	-0.95	-0.68	-0.87	-0.63		-0.78	0.99	-0.74	0.57	0.64
Net Working Capital	0.96	0.78	-0.79	-0.75	0.64	0.41	0.97	0.96	0.82	0.78	0.93	0.81	0.89	0.87	0.93	-0.78		-0.75	0.81	-0.53	-0.66
Short Term Debt	-0.82	-0.75	0.8	0.7	-0.68	-0.43	-0.8	-0.82	-0.85	-0.81	-0.8	-0.93	-0.67	-0.82	-0.61	0.99	-0.75		-0.68	0.49	0.57
Capital Stock	0.85	0.73	-0.84	-0.97	0.92	0.67	0.84	0.85	0.89	0.75	0.92	0.81	0.5	0.87	0.59	-0.74	0.81	-0.68		-0.82	-0.95
Current Deferred Revenue	-0.5	-0.47	0.57	0.91	-0.9	-0.92	-0.49	-0.51	-0.59	-0.62	-0.63	-0.67	-0.26	-0.73	-0.35	0.57	-0.53	0.49	-0.82		0.9
Short Term Investments	-0.67	-0.6	0.8	0.96	-0.94	-0.7	-0.66	-0.67	-0.76	-0.67	-0.77	-0.72	-0.29	-0.78	-0.4	0.64	-0.66	0.57	-0.95	0.9

Click cells to compare fundamentals

Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.

Competition

Predict Apellis Pharmaceuticals

In accordance with the recently published financial statements, Apellis Pharmaceuticals has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Portfolio Center Now

Portfolio Center

All portfolio management and optimization tools to improve performance of your portfolios

All Next

Launch Module

Apellis Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Apellis Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Apellis Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Apellis Fundamentals

	Return On Equity	-1.07
	Return On Asset	-0.16
	Profit Margin	(0.35) %
	Operating Margin	(0.24) %
	Current Valuation	4.32 B
	Shares Outstanding	124.39 M
	Shares Owned By Insiders	13.98 %
	Shares Owned By Institutions	98.75 %
	Number Of Shares Shorted	23.18 M
	Price To Earning	(6.94) X
	Price To Book	17.91 X
	Price To Sales	5.94 X
	Revenue	396.59 M
	Gross Profit	69.79 M
	EBITDA	(495.21 M)
	Net Income	(528.63 M)
	Cash And Equivalents	852.8 M
	Cash Per Share	7.76 X
	Total Debt	110.93 M
	Debt To Equity	0.63 %
	Current Ratio	7.57 X
	Book Value Per Share	1.94 X
	Cash Flow From Operations	(594.74 M)
	Short Ratio	7.27 X
	Earnings Per Share	(2.03) X
	Price To Earnings To Growth	(0.30) X
	Target Price	45.75
	Number Of Employees	702
	Beta	0.87
	Market Capitalization	4.25 B
	Total Asset	788.73 M
	Retained Earnings	(2.84 B)
	Working Capital	518.74 M
	Current Asset	115.82 M
	Current Liabilities	5.13 M
	Net Asset	788.73 M

About Apellis Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Apellis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC